SS
STLN

SBI Securities’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

SBI Securities’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.69K Buy
+1,600
New +$6.72K ﹤0.01% 1910
2026
Q1 		– Sell
-3,500
Closed -$12.5K – 4154
2025
Q4 		$12.5K Hold
3,500
– – ﹤0.01% 1627
2025
Q3 		$12.2K Buy
3,500
+500
+17% +$1.71K ﹤0.01% 1679
2025
Q2 		$6.15K Buy
3,000
+2,800
+1,400% +$7K ﹤0.01% 1890
2025
Q1 		$228 Buy
+200
New +$155 ﹤0.01% 3177

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

SBI Securities's STLN Position: Q2 2026 in Review

SBI Securities opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2026: 1,600 shares worth $8.69K. The stake represents ﹤0.01% of the portfolio and ranks #1910 among its holdings. This is a return to the name: SBI Securities previously reported a position in STLN as recently as Q4 2025.

SBI Securities first reported a position in STLN in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.5K in Q4 2025. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • SBI Securities held 1,600 shares of Starling Oncology Institute, Inc. Common Stock worth $8.69K as of Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new SBI Securities position in Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1910 holding.
  • SBI Securities first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2025 and has held it in 5 quarters since.
  • SBI Securities's Starling Oncology Institute, Inc. Common Stock position peaked at $12.5K in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.